Podcasts about molecular therapy

Die Themen in den Wissensnachrichten: +++ Wenn gedüngt wird, gibt es weniger Blumen und Bienen +++ Besondere Bakterien sollen gegen Krebs helfen +++ Falschinformationen erkennen fällt vielen schwer +++**********Weiterführende Quellen zu dieser Folge:Trade-off between pollinator-wildflower diversity & grassland yields, npj biodiversity, 20.01.25Controlling intracellular protein delivery, tumor colonization and tissue distribution using the master regulator flhDC in a clinically relevant ΔsseJ Salmonella strain, Molecular Therapy, 30.12.24Studie: Desinformation unter jungen Menschen weit verbreitet, Friedrich Naumann Stiftung, 20.01.25Spatial overlap: trade-offs in refugees' residential choices, Journal of Ethnic and Migration Studies, 12.11.24Examining Preliminary Efficacy of a Qigong Intervention in Veterans with Chronic Low Back Pain: A Randomized Controlled Pilot Study, Pain Management Nursing, 22.11.24Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok auf&ab , TikTok wie_geht und Instagram .

Join Dr. Paloma Giangrande, Editor-in-Chief of Molecular Therapy Nucleic Acids, as she discusses RNA exon editing with Ascidian Therapeutics' leadership: CSO Dr. Robert Bell and CEO Dr. Michael Ehlers. Their conversation explores Dr. Bell's recent MTNA publication "RNA Exon Editing: Splicing the Way to Treat Human Diseases." Last Call: Submit your abstracts for ASGCT's 2025 Annual Meeting in New Orleans by January 31st, 11:59 PM ET. Present at cell and gene therapy's premier event and get published in Molecular Therapy. Details at annualmeeting.asgct.org/abstracts. In This Episode Paloma Giangrande, PhDEditor-in-Chief, Molecular Therapy Nucleic Acids and Chief Technology Officer at Eleven Therapeutics Robert Bell, PhDChief Scientific Officer at Ascidian Therapeutics Michael Ehlers, MD, PhDPresident and Chief Executive Officer at Ascidian Therapeutics 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

This episode features a conversation between Dr. Timothy Cripe and Dr. Joseph Glorioso, who discuss an article published in Molecular Therapy Oncology by Dr. Glorioso and colleagues titled Oncolytic Herpes Simplex Viruses Designed for Targeted Treatment of EGFR-bearing Tumors. Join the editor-in-chief of Molecular Therapy, Dr. Roland Herzog, and ASGCT this January for the next installment of Molecular Therapy Presents: Clinical Gene and Cell Therapy. This transformative field has grown from promising experimental treatments to approved medicines for a wide range of genetic and/or acquired diseases. This virtual event is free for ASGCT members to attend and will highlight several in-depth invited reviews appearing in Molecular Therapy's Clinical Gene and Cell Therapy special issue. Attend the webinar and learn more about cutting-edge developments in the clinical space before the special issue is published in early 2025. Find Molecular Therapy Presents: Clinical Gene and Cell Therapy, and all upcoming ASGCT events at ASGCT.org/events.  In This Episode Timothy Cripe, MD, PhDEditor-in-Chief, Molecular Therapy Oncology and Professor and Chief of Hematology, Oncology, BMT at Nationwide Children's Hospital Dr. Joseph GloriosoProfessor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

This episode features a conversation between Dr. Roland Herzog and Dr. Joseph Glorioso. On January 1, 2025, Dr. Glorioso will begin his 5-year term as the Editor-in-Chief of Molecular Therapy, marking the end of Dr. Herzog's successful tenure at the helm of the journal. Drs.Herzog and Glorioso engage in a wide-ranging conversation that touches on the history of Molecular Therapy, highlights from the gene and cell therapy field, and how Molecular Therapy will continue to grow and evolve under Dr. Glorioso's leadership. ASGCT is proud to present this episode of the Molecular Therapy Podcast in partnership with our upcoming Breakthroughs in Muscular Dystrophy conference on November 19th and 20th in Chicago, and virtually This event will provide an unparalleled opportunity to delve into the latest advancements in research on gene and cell therapies for muscular dystrophy. Learn more and register today at ASGCT.org/Breakthroughs. In This Episode: Dr. Roland HerzogEditor-in-Chief of Molecular Therapy and Professor of Pediatrics, Riley Children's Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University Dr. Joseph GloriosoProfessor, Department of Microbiology and Molecular Genetics and Department of Human Genetics at the University of Pittsburgh 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Drs. Beverly Davidson and Bryan Simpson join Molecular Therapy EiC Dr. Roland Herzog to discuss their recent paper, Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in the brain, which was published in Molecular Therapy. ASGCT is proud to present this episode of the Molecular Therapy Podcast in partnership with our upcoming Advancing Gene and Cell Therapy for Cancer conference, which will be held on October 16 and 17 in Philadelphia and online. This landmark hybrid event brings together innovative treatment approaches and an unparalleled opportunity to immerse yourself in the latest gene and cell therapy research for cancer. Learn more and register today at ASGCT.org/Advancing. In This Episode: Dr. Roland HerzogEditor-in-Chief of Molecular Therapy and Professor of Pediatrics, Riley Children's Foundation Professor of Immunology, and Director of the Gene and Cell Therapy Program at Indiana University Dr. Beverly DavidsonChief Scientific Strategy Officer and Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics at Children's Hospital of Philadelphia Dr. Bryan SimpsonPreclinical Team Lead at Latus Bio 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join ASGCT and the Molecular Therapy family of journals for a conversation between Drs. Paloma Giangrande and Marcin Kortylewski. They discuss a recent article published in Molecular Therapy Nucleic Acids by Dr. Kortylewski and colleagues titled "Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3." If you enjoy today's conversation, you'll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, September 23-24.  This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Dr. Nicole Verdun, to discuss the latest policies impacting this rapidly evolving field.  Register now at https://www.asgct.org/PolicySummit for invaluable insights on navigating the regulatory landscape.  In This Episode: Dr. Paloma GiangrandeEditor-in-Chief of Molecular Therapy Nucleic Acids and Chief Technology Officer at Eleven Therapeutics Dr. Marcin KortylewskiProfessor, Department of Immuno-Oncology at City of Hope 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dr. Daniel Stone speaks with Drs. Mario Mietzsch and Robert McKenna from the University of Florida to discuss a recent article published in the Biomanufacturing in Gene and Cell Therapy special issue of Molecular Therapy Methods & Clinical Development by Drs. Mietzsch, McKenna, and colleagues titled Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard. If you enjoy today's conversation, you'll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, September 23-24.  This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Dr. Nicole Verdun, to discuss the latest policies impacting this rapidly evolving field.  Register now at https://www.asgct.org/PolicySummit for invaluable insights on navigating the regulatory landscape.  In This Episode: Dr. Daniel StoneAssociate Editor-in-Chief of Molecular Therapy Methods & Clinical Development and Senior Staff Scientist, Infectious Disease Sciences, Vaccine and Infectious Disease Division at Fred Hutch Cancer Center Dr. Mario MietzschAssistant Scientist, Department of Biochemistry and Molecular Biology, University of Florida Dr. Robert McKennaProfessor and Director of the Center for Structural Biology, Department of Biochemistry and Molecular Biology, University of Florida 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Mohamed Abou-el-Enein, MD, PhD, MSPH, the new editor-in-chief of Molecular Therapy Methods & Clinical Development (MTMCD), sits down with Scientific Editor Rory Bricker-Anthony, PhD, to discuss his vision for the journal. If you enjoy today's conversation, you'll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, on September 23 and 24. This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Nicole Verdun, PhD, to discuss the latest policies impacting this rapidly evolving field. Register now at ASGCT.org/PolicySummit for invaluable insights on navigating the regulatory landscape. Virtual attendance options are also available. Dr. Abou-el-Enein has served as MTMCD's associate editor-in-chief for the past two years, which will allow him to make a smooth transition in leadership. His vision for MTMCD is consistent innovation, evolution, and growth. Dr. Abou-el-Enein firmly believes that MTMCD has the potential to become a leading voice in the gene and cell therapy landscape. He is eager to leverage his experience and expertise to expand the journal's reach and impact.  Dr. Abou-el-Enein is an associate professor of clinical medicine (oncology), pediatrics, and stem cell biology and regenerative medicine at USC Keck School of Medicine as well as executive director of the USC/CHLA cell therapy program. He is an internationally recognized expert in planning and executing clinical development programs, designing and operating academic GMP facilities, and translating cell and gene therapy products from preclinical research to clinical applications. His research laboratory is dedicated to pioneering advancements in CAR T-cell therapies, including optimizing engineering techniques and devising novel strategies for allogeneic applications and genetic delivery tools to increase accessibility and scalability. 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join Drs. Timothy Cripe and Marco Davila as they discuss a recent article published in the December issue of Molecular Therapy Oncology by Dr. Davila and colleagues titled, Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Dr. Timothy Cripe: Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children's Hospital Dr. Marco Davila, Rustum Family Endowed Chair in Translational Research, Senior Vice President and Associate Director for Translational Research, Department of Medicine and Immunology, Roswell Park Comprehensive Cancer Center Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals ASGCT members save $385 on registration rates for the ASGCT Annual Meeting whether you're attending in person or virtually! Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at annualmeeting.asgct.org. 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dr. Roland Herzog sits down with Drs. David Schaffer and Adam Schieferecke to discuss a recent article published in the February issue of Molecular Therapy by Drs. Schaffer and Schieferecke and colleagues titled, Evolving membrane-associated accessory protein variants for improved adeno-associated virus production. Read the full article: https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(23)00679-2 Dr. Roland Herzog: Editor-in-Chief of Molecular Therapy and Professor of Pediatrics at Indiana University Dr. David Schaffer: Hubbard Howe Jr. Distinguished Professor, Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, and the Helen Wills Neuroscience Institute, University of California at Berkeley Dr. Adam Schieferecke: Postdoctoral Scholar, California Institute for Quantitative Biosciences, University of California at Berkeley.  ASGCT members save $385 on registration rates for the Annual Meeting whether you're attending in person or virtually—that's a bigger savings than the cost of membership itself, by the way. Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at annualmeeting.asgct.org. Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Today we have a very special guest on The Issue: Federico Mingozzi, PhD. Federico's first ASGCT podcast could have easily been on Giants of Gene Therapy. Still, we're excited that he could join us for an in-depth chat about his career journey and AAV immunogenicity. Dr. Mingozzi has done seminal work throughout his career in AAV gene therapy, and his 2020 Molecular Therapy review of our current understanding of the immune reaction to these therapies is a must-read for anyone trying to get a handle on the very complicated landscape of immune reactions to viral vectors. Have you registered for the ASGCT Annual Meeting yet? Meet us in Baltimore, May 7-11, for the only must-attend event in cell and gene therapy. There's no better place to deep dive in this field than the ASGCT Annual Meeting—you will not find the same breadth or depth of CGT research anywhere in the world. Check out the full program and learn more about the meeting at www.annualmeeting.asgct.org. Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join Drs. Paloma Giangrande (Editor-in-Chief of Molecular Therapy Nucleic Acids and Chief Technology Officer at Eleven Therapy) and Maxim Berezovski (Professor of Bioanalytical Chemistry at the University of Ottawa). They will discuss a recent article published in Molecular Therapy Nucleic Acids by Dr. Berezovski and colleagues titled, Discovery of DNA aptamers targeting SARS-CoV-2 nucleocapsid protein and protein-binding epitopes for label-free COVID-19 diagnostics. Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

This episode features a conversation between Dr. Richard Vile, Professor of Immunology at Mayo Clinic and Dr. Timothy Cripe, Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children's Hospital. They will discuss a recent article published in the June issue of Molecular Therapy Oncology by Dr. Vile and colleagues titled, "Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses." Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Welcome to the first episode of the Molecular Therapy Podcast! Join Dr. Roland Herzog, Editor-in-Chief of Molecular Therapy and Professor of Pediatrics at Indiana University, and Dr. Norbert Pardi, Assistant Professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, as they discuss a recent article published in the September issue of Molecular Therapy by Dr. Pardi and colleagues titled, "Development of an mRNA-lipid Nanoparticle Vaccine Against Lyme Disease." Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Episode 22. A conversation with Prof Thomas Ritter who, with his team in University of Galway, is embarking on a journey of advancing treatments for rare eye diseases in Europe. Restore Vision is a project funded by the European Commission aiming to develop and test new treatments for 7 rare eye diseases (REDs). The consortium joins 10 European key players on rare eye diseases and is led by University of Galway. With 25+ years of experience in immunology and gene therapies for eye diseases, Prof. Ritter's research focuses on novel gene and cell therapies. He earned his Ph.D. in 1994 from the University of Erlangen-Nuremberg, Germany, and completed his Post-Doctoral Fellowship at the Marseille Center of Immunology in 1995. At Charité University Hospital in Berlin, Germany, Prof. Ritter led the gene therapy program in experimental transplantation under Prof. Volk's directorship. He obtained significant funding from the German Research Foundation, Ministry of Health and Research, and industry (Schering). In 2002, he completed his ‘Habilitation' in Immunology, becoming an assistant professor in 2003. Since joining the University of Galway in 2005, Prof. Ritter secured significant funding from various agencies, totaling approximately €7M. He has published 90+ research articles and 30 reviews in peer-reviewed journals, delivered 50+ invited lectures, and served as Vice-Dean for Research at NUI Galway. He is an Associate Editor for Molecular Therapy, serves as a referee for high-impact journals, and is involved in multiple European networks for Cooperation in Science and Technology (COST-Action). For more information visit: https://restorevision-project.eu https://www.aniridia.eu  

Pastilha elástica com uma proteína reduz carga viral na saliva em mais de 90%. Ainda está em fase experimental. Estudo publicado no Molecular Therapy

Join us for a continuation of our conversation with David Barrett, CEO of the American Society of Gene & Cell Therapy, on successfully navigating the changing medical conference landscape. David will speak to designing medical conferences that deliver value and opportunity for all those involved. He will touch on scientific posters, metrics, patient inclusion in medical conferences, and the need to translate complex information into more digestible formats, even for HCPs. Be better prepared for the medical conferences of the future!  InformED is generously sponsored by MedThink SciCom. Follow ISMPP on Twitter, LinkedIn and YouTube Host Robert J. Matheis is currently the President and CEO of the International Society for Medical Publication Professionals.  Previous to this, he was Executive Director and Head of Global Scientific Communications with Celgene Corporation after serving as Senior Director of Evidence Based Medical Communications with Sanofi.  Dr. Matheis has a long tenure within scientific and medical communications and has been an integral part of ISMPP for more than a decade.   Guest David Barrett, JD, MS, is the CEO of the American Society of Gene & Cell Therapy, the largest society of gene and cell therapy scientists, researchers, and other professionals. ASGCT hosts an annual scientific conference, more than ten additional workshops and symposia each year, and publishes four academic journals within its Molecular Therapy family of journals, among other programs. In this role, David is responsible for the oversight and execution of all facets of ASGCT's operations, including organizational management and program execution. Since 2016, he has led the Society's efforts to expand its annual conference, build a legislative and regulatory advocacy function, establish a series of career development awards, and facilitate a robust patient education and advocacy program. In 2020, ASGCT virtual events are projected to attract more than 10,000 individual attendees and its patient education efforts to reach roughly 100,000 viewers.

Medical societies have had to innovate rapidly in light of cancelled conferences during the pandemic. Innovation was accelerated, and the virtual conference emerged. Join us for an insightful conversation with David Barrett, the CEO of the American Society of Gene & Cell Therapy, which is the largest society of gene and cell therapy scientists, researchers, and other professionals. In Part 1 of the discussion, David will speak to successfully navigating the changing medical conference landscape and what the future might hold. What are attendees really looking for? What formats have been most successful for engagement?  InformED is generously sponsored by MedThink SciCom. Follow ISMPP on Twitter, LinkedIn and YouTube Host Robert J. Matheis is currently the President and CEO of the International Society for Medical Publication Professionals.  Previous to this, he was Executive Director and Head of Global Scientific Communications with Celgene Corporation after serving as Senior Director of Evidence Based Medical Communications with Sanofi.  Dr. Matheis has a long tenure within scientific and medical communications and has been an integral part of ISMPP for more than a decade.   Guest David Barrett, JD, MS, is the CEO of the American Society of Gene & Cell Therapy, the largest society of gene and cell therapy scientists, researchers, and other professionals. ASGCT hosts an annual scientific conference, more than ten additional workshops and symposia each year, and publishes four academic journals within its Molecular Therapy family of journals, among other programs. In this role, David is responsible for the oversight and execution of all facets of ASGCT's operations, including organizational management and program execution. Since 2016, he has led the Society's efforts to expand its annual conference, build a legislative and regulatory advocacy function, establish a series of career development awards, and facilitate a robust patient education and advocacy program. In 2020, ASGCT virtual events are projected to attract more than 10,000 individual attendees and its patient education efforts to reach roughly 100,000 viewers.

Jeff Galvin is the CEO & Founder of American Gene Technologies (AGT), a clinical-stage biotech company with a proprietary gene-delivery platform for rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. He earned his BA degree in Economics from Harvard in 1981 and accumulated more than 30 years of business and entrepreneurial experience while founding and leading a variety of Silicon Valley startups. As a retired angel investor, Mr. Galvin funded and founded AGT after meeting with Dr. Roscoe Brady, a research scientist at NIH-NINDS who is best known for developing the first ever enzyme replacement therapy called Alglucerase that treats Gaucher disease and is marketed by Sanofi Genzyme. In this episode, we discuss how the company initially came together, the science behind AGT’s gene & cell therapy platform, and the rationale behind their lead drug candidate - a first-in-class, genetically modified T-cell therapy developed as a functional cure for HIV, which entered first-in-human Phase 1 clinical trials in November 2020 (AGT press release, Molecular Therapy paper). Mr. Galvin also shares his unique perspective about how the principles that drove the success of the computer & software industries are starting to bleed into the biotech industry, making drug development more fruitful and cost effective.Hosted by Joe Varriale and Roshan Chikarmane.

Understanding how molecular therapy can be used to help people. Learn how the study of the zebra fish relates to heart repair therapy

Norris Cotton Cancer Center Grand Rounds presented on April 24, 2018 Justin M. Balko, Pharm.D. Ph.D Assistant Professor, Department of Medicine Cancer Biology Program Vanderbilt University Medical Center Leader of Molecular Oncology, Center for Cancer-Targeted Therapies Vanderbilt Ingram Cancer Center

Scientists have found a way to remove the HIV virus from the DNA in mouse cells using CRISPR/Cas9 technology. According to the journal, Molecular Therapy, use of the technique has led to the complete elimination of infection in mouse organs and tissue after just one treatment. Now, that's the kind of international tech news that really gets us excited around here! And, yes! The team at the African Tech Round-up is back from a much-needed break, and we're super-stoked to catch up on news like this CRISPR HIV breathrough, as well as dive into some of the other significant headlines that dropped while we were away. We're pleased to announce that Musa Kalenga will be joining Andile as a guest co-host on the show every fortnight starting this week to chat about the most important stories and to unpack major trends impacting Africa's tech ecosystem. Music Credits: Music by Kevin MacLeod (incompetech.com) Music licensed under Creative Commons: By Attribution 3.0

From neuropathology to molecular target to clinical treatments, where are we on the road to finding an effective treatment for Alzheimer's disease? Howard Feldman, MD, FRCP(C), a neurologist noted for his original research in geriatric cognitive disorders and expertise in large-scale clinical trials, walks through the latest research and shares some tips on brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Science] [Show ID: 31035]

From neuropathology to molecular target to clinical treatments, where are we on the road to finding an effective treatment for Alzheimer's disease? Howard Feldman, MD, FRCP(C), a neurologist noted for his original research in geriatric cognitive disorders and expertise in large-scale clinical trials, walks through the latest research and shares some tips on brain health. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Science] [Show ID: 31035]

Harry Bear discusses the use of adjuvant and neoadjuvant bevacizumab in the treatment of early breast cancer.

Robert Hills discusses a meta-analysis of gemtuzumab ozogamicin for the treatment of adult myeloid leukaemia.

Dr. Louis Chicoine Discusses the Effect of Plasmapheresis in Removal of AAV Antibodies for Gene Therapy :: November 2013 Guest: Louis Chicoine, MD, principal investigator in the Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital; assistant professor of Pediatrics at The Ohio State University College of Medicine. Access an abstract of this month’s featured research article: Plasmapheresis eliminates the negative impact of AAV antibodies on micro-dystrophin gene expression following vascular delivery. Molecular Therapy. 2013 Oct 23. [Epub ahead of print] Major contributors to the work described include the Jesse’s Journey Foundation, the Nationwide Children’s Hospital Foundation, the Muscular Dystrophy Association, a National Institutes of Health grant (U54 NS055958), and a Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center grant (U54 HD066409).

Dr. Louis Chicoine Discusses the Effect of Plasmapheresis in Removal of AAV Antibodies for Gene Therapy :: November 2013 Guest: Louis Chicoine, MD, principal investigator in the Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital; assistant professor of Pediatrics at The Ohio State University College of Medicine. Access an abstract of this month’s featured research article: Plasmapheresis eliminates the negative impact of AAV antibodies on micro-dystrophin gene expression following vascular delivery. Molecular Therapy. 2013 Oct 23. [Epub ahead of print] Major contributors to the work described include the Jesse’s Journey Foundation, the Nationwide Children’s Hospital Foundation, the Muscular Dystrophy Association, a National Institutes of Health grant (U54 NS055958), and a Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center grant (U54 HD066409).

Ramon Luengo-Fernandez discusses the cost of cancer care in the European Union.

Kathy Pritchard-Jones discusses a Series about paediatric oncology.

Guest: Ken Fujise, MD Host: Janet Wright, MD Targeted molecular therapy has been successful in cancer therapeutics. How might this approach be applied in cardiology to prevent the development of atherosclerosis? Dr. Ken Fujise, chief of cardiology at University of Texas Medical Branch, where he is also professor of medicine and biochemistry and molecular biology, talks about his preliminary research investigating the role of fortilin in the progression of atherosclerosis and subsequent coronary artery disease. What are the prospects for development of anti-fortilin medication to prevent or slow atherosclerosis? Dr. Janet Wright hosts. Produced in Cooperation with

Guest: Ken Fujise, MD Host: Janet Wright, MD Targeted molecular therapy has been successful in cancer therapeutics. How might this approach be applied in cardiology to prevent the development of atherosclerosis? Dr. Ken Fujise, chief of cardiology at University of Texas Medical Branch, where he is also professor of medicine and biochemistry and molecular biology, talks about his preliminary research investigating the role of fortilin in the progression of atherosclerosis and subsequent coronary artery disease. What are the prospects for development of anti-fortilin medication to prevent or slow atherosclerosis? Dr. Janet Wright hosts. Produced in Cooperation with

11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor status to the choice of molecular therapy for patients with metastatic colorectal cancer. Whether the gene is wild-type or mutant determines sensitivity of the tumor to anti-epidermal growth factor or anti-vascular endothelial growth factor receptor therapy. Dr Macdonald also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.

Interviewed at the Palm Beach Cancer Symposium, John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data on the relevance of KRAS tumor status—i.e., whether the gene is wild-type or mutant determines the sensitivity of the tumor to anti-EGF or anti-VEGF receptor therapy. He also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.

Interviewed at the Palm Beach Cancer Symposium, John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data on the relevance of KRAS tumor status—i.e., whether the gene is wild-type or mutant determines the sensitivity of the tumor to anti-EGF or anti-VEGF receptor therapy. He also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.

Thu, 26 Jun 2003 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/1242/ https://edoc.ub.uni-muenchen.de/1242/1/Dunant_Patrick.pdf Dunant, Patrick ddc:540, ddc:500, Fakultät für Chemie und Pharmazie